Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — 2025 Military Health System Research Symposium
21 slides from Cocrystal Pharma's conference presentation, Aug 5, 2025
Slide 1: 2025 Military Health System Research Symposium
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our development pipeline; our technology platform’s ability to produce viable drug candidates at reduced development timelines and co
Slide 3: About Cocrystal Pharma
About Cocrystal Pharma = Advancing programs in direct-acting small molecule antivirals ° Norovirus + Influenza Applying powerful, proprietary * Coronavirus and respiratory viruses drug discovery platform technology to develop first- and best-in-class broad-spectrum antiviral drugs = Drug candidates
Slide 4: Proprietary Drug Discovery Platform Technology for Direct-Acting Antivirals
Proprietary Drug Discovery Platform Technology for Direct-Acti Cocrystal’s technology platform provides potential for novel drug candidates at reduced development timelines and costs Grow drug target _ Select drug Hit-to-lead Lead . . — X-ray crystals binding pocket process optimization Direct-Actin
Slide 5: Robust Pipeline
Robust Pipelin« Program Candidate (Oral PB2 inhibitor cc-42344 Inhaled PB2 inhibitor cc-42344 Replication inhibitors ‘Oral Pan-viral protease inhibitor col-988, Norovirus & Coronavirus Norovirus Replication inhibitors Pan-viral inhibitors: Respiratory viruses
Slide 6: Restaurants / Nursing homes
Restaurants = Nursing homes
Slide 7: Norovirus Viral Gastroenteritis Represents Significant Unmet Need
/ Norovirus Viral Gastroenteritis Represents Significant Unmet Need No treatment or vaccines available ly worldwide Norovirus GIL pandemic outbreaks Norovirus Leading causative agent offacute viral gastroenteritis 109K Hospitalizations annually inthe US >19M Revotad cases Shayne Cocrystal’s Antivira
Slide 8: Why the 'Ferrari of viruses' is surging through the Northern Hemisphere
Why the ‘Ferrari of viruses’ is surging through the Northern Hemisphere Norovirus, which causes explosive diarrhea and vomiting, may be on the rise because of an antibody-dodging variant VID-19 socializ and po: 5 - 6:00 PMET - BY Norovirus concentration in wastewater (Normalized x1000) 250 200 150 1
Slide 9: Norovirus GII.17 Has Rapidly Overtaken GII.4
Norovirus GIl.17 Has Rapidly Overtaken GIlI.4 As The Leading Cause of Norovirus Outbreaks, >70% A. Gil.17 (n = 861) woos = Noroviruses are genetically diverse: ‘ > 10 genogroups are subdivided into different genotypes, currently 49 genotypes S. — ee A ° > - & e o > ° os ff oft $ a é s B.Gll.g (n= 6,
Slide 10: Cocrystal's Protease Inhibitor CDI-988 Blocks the Viral Essential Replication Process
Cocrystal’s Protease Inhibitor CDI-988 Blocks the Viral Essential Replication Process Norovirus or SARS-CoV-2 Infected cell Membrane fusion Assembly and Endocytosis Release Uncoating ‘Non-structural Structural RNA Polyproteins RNA proteins Translation Proteolysis Replication Translation Cocrystal’s
Slide 11: Cocrystal's Structure-Based Drug Discovery Platform Technology
Cocrystal’s Structure-Based Drug Discovery Platform Technology For Pan-viral Protease Inhibitor Development Cocrystal pan-viral inhibitors target highly conserved viral protease active site SARS-Cov-2 SARS-Cov-1 MERS-CoV Norovirus \ 4 P Highly conserved cysteine residue Highly conserved cysteine res
Slide 12: Cocrystal's CDI-988 for All Norovirus and Coronavirus
Cocrystal’s For All Nore orov Binds to highly conserved region of the viral protease active site ™ Exhibits broad-spectrum, potent antiviral activity against all norovirus and coronavirus proteases CDI-988 CDI-988 CDI-988 CDI-988 . i Y i (B) SARS-CoV-2 Developed using Cocrystal’s proprietary drug di
Slide 13: Phase 1 Study of First-in-Class Direct-Acting Oral Antiviral Protease Inhibitor CDI-988
Phase 1 Study of First-in-Class Direct-Acting Oral Antiviral Protease Inhibitor; CDI-988 A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of Oral CDI-988 in Heal
Slide 14: Oral Pan-viral Protease Inhibitor CDI-988 Showed Favorable Safety and Tolerability
Oral Pan-viral Protease Inhibitor CDI-988 Showed Favorable Safety and Tolerability, ™ Single-center, randomized, double-blind, placebo-controlled ™ Single-ascending dose (SAD) and Multiple-ascending dose (MAD) cohorts ™ Healthy adult volunteers (18 — 55 years old) Each cohort comprised 8 participant
Slide 15: Key Entry Criteria
Key Entry Criteria Healthy males and females 2 18 and < 55 years Body weight 2 50 kg Body mass index > 18 and < 32 kg/m? Non-pregnant, non-lactating Must abstain from alcohol or caffeine from 48 hours before study confinement through duration of study Must not have taken prescribed medication in 14
Slide 16: Demographics of SAD and MAD cohorts
Demographics of SAD and MAD cohorts Placebo Placebo (N=10) (N=12) Beer) 295 32.5 30.0 30.6 Mean . 27.6 27.4 283 29.6 Median 21-49 20-56 21-45 25-39 Range Male, n (%) 14 (39%) 2 (20%) 23 (64%) 7 (58%) Female 22 (61%) 8 (80%) 13 (36%) 5 (42%) Ethnicity, n (%) Hispanic or Latino 1(8%) 3 (30%) 9 (25%) 5
Slide 17: SAD Clinical Safety Summary (N=46)
SAD Clinical Safety Summary (N=46) = All dose cohorts well tolerated (100mg to 1200mg) = Safety profile + 100% of AEs were mild severity (CDI-988 (N=11, 100%) vs Placebo (N= 4, 100%)) * Only 7 treatment-related AEs across all dose cohorts (CDI-988 (N=5, 14%) vs Placebo (N=2, 20%)) + Most commonly oc
Slide 18: MAD Clinical Safety Summary (N=48)
MAD Clinical Safety Summary (N=48) = All dose cohorts well tolerated (200mg to 1200mg) = Safety profile + Total of 30 reported AEs (CDI-988 (N=19, 53%) vs Placebo (N=11, 92%)) * 26 of these were mild severity (CDI-988 (N=16, 84%) vs Placebo (N=10, 91%)) * 8AEs of moderate severity (CDI-988 (N=4, 21%
Slide 19: CDI-988 Demonstrates Strong Food Effect
CDI-988 Demonstrates Strong Food Effect 19 —©~ Cohort 10-400 mg-Fasted —®~ Cohort 1C-400mg—Fed ‘Concentration (ngimL) 2500 ‘Linear Axes 2000 am Fed 1500 1000 am Fasted ‘Concentration (ngimL.) 10000 ‘Semi-Logarithinic Axes 1000 =m Fed 100 Fasted High fat meal prior to dosing results in a 5- to 6-fold
Slide 20: Topline Safety Data Summary and Next Steps
Topline Safety Data Summary and Next Steps SAD cohorts Overall treatment-emergent AE (TEAE) rate Overall treatment-emergent (TEAE) rate = 28% (10/36) in CDI-988 cohorts = 53% (19/36) in CDI-988 cohorts = 40% (4/10) in placebo subjects = 92% (11/12) in placebo subjects Headache was the most frequentl
Slide 21: Slide 21
Cocrystal Pharma — 2025 Military Health System Research Symposium on 6ix